Search

Stephen G Oroszlan

from Potomac, MD
Age ~97
Get Report
Also known as:
Steve G Oroszlan, Stephen Orlove, H Oroszlan, Stephen N
Phone and address:
11411 Duryea Dr, Rockville, MD 20854
(301) 299-2258
Related to:
Rosemary HanrahanCynthia Mealey, 77Steven Jette, 55Carlie CavanaughJeanne Jette, 81
Connected to:
Francis C Oroszlan, 41Peter J Oroszlany, 54Mark D Orotosky, 60Steven J Orova, 57John J Orovecz, 75Iridio J Orovio, 39Julian Orovio, 69Danielle M Orow, 70Nicholas R Orow, 45Andrew P Orowitz, 46

Stephen Oroszlan Phones & Addresses

  • 11411 Duryea Dr, Potomac, MD 20854 (301) 299-2258 (301) 299-9877
  • Rockville, MD
  • Bellevue, WA
  • 11411 Duryea Dr, Potomac, MD 20854

Work

Position: Medical Professional

Education

Degree: Graduate or professional degree

Emails

o***[email protected]

Resumes

Resumes

Stephen Oroszlan Photo 1

Stephen Oroszlan

View page
Location:
United States

Publications

Us Patents

Human Immunodeficiency Virus Specific Proteolytic Enzyme And A Method For Its Synthesis And Renaturation

View page
US Patent:
52524779, Oct 12, 1993
Filed:
Jun 1, 1987
Appl. No.:
7/057183
Inventors:
Stephen Oroszlan - Potomac MD
Terry D. Copeland - Frederick MD
Assignee:
The United States of America as represented by the United States
Department of Health and Human Services - Bethesda MD
International Classification:
C12N 950
C12N 704
C12N 1584
US Classification:
435219
Abstract:
HIV protease necessary for the natural synthesis of HIV has been identified and sequenced. Rabbit antiserum against the C-terminal portion of HIV protease has been produced and used to isolate natural HIV protease and characterize its activity. In addition, a method for producing synthetic HIV protease having the correct stereospecific conformation and specific HIV proteolytic activity has been achieved.

2,3-Epoxy Derivatives As Anti Retrovital Chemotherapeutic Agents

View page
US Patent:
51909693, Mar 2, 1993
Filed:
Dec 20, 1988
Appl. No.:
7/286977
Inventors:
Jeffrey J. Blumenstein - Germantown MD
Christopher J. Michejda - Potomac MD
Stephen Oroszlan - Potomac MD
Terry Copeland - Frederick MD
Assignee:
The United States of America as represented by the Secretary of the
Department of Health & Human Services - Washington DC
International Classification:
A61K 3140
A61K 31335
US Classification:
514422
Abstract:
The present invention is related to compounds, compositions and methods of treating viral infections. Compounds of the present invention have the following general formula: ##STR1## wherein R is selected from --CH. sub. 2 OH, --CO. sub. 2 R. sup. 2, --CONR. sup. 3 R. sup. 4, or COR. sup. 5, wherein R. sup. 2 is hydrogen or a lower alkyl group, R. sup. 3 and R. sup. 4 are each independently hydrogen or a lower alkyl group, R. sup. 5 is an amino acid residue bound via a terminal nitrogen or peptide having at least two amino acid residues; and wherein R. sup. 1 is C. sub. 5 -C. sub. 13 alkyl, aryl, aralkyl, aralkyl(lower alkyl) ether, or C. sub. 5 -C. sub. 13 alkyl (lower alkyl)ether.

Inhibition Of Human Immunodeficiency Virus-1 Infectivity In Human Cells

View page
US Patent:
56681496, Sep 16, 1997
Filed:
Jan 26, 1990
Appl. No.:
7/470692
Inventors:
Stephen Oroszlan - Potomac MD
Wen-Po Tsai - Walkersville MD
Peter L. Nara - Frederick MD
Hsiang-Fu Kung - Middletown MD
Assignee:
The United States of America as represented by the Department of Health
and Human Services - Washington DC
International Classification:
A61K 3147
US Classification:
514313
Abstract:
Methods are disclosed for inhibiting the infectivity of HIV-1 in human cells. The methods comprise contacting human cells infected with HIV-1, with certain quinolinyl and acridinyl derivatives, including amodiaquin, chloroquine, hydroxychloroquine, primoquine, quinacrine and compounds having the formula: ##STR1## wherein R. sup. 1 and R. sup. 2 are each hydrogen, or join to form a cyclic structure of the formula: ##STR2## and R. sup. 3 and R. sup. 4, same or different, are hydrogen, C. sub. 1 -C. sub. 8 lower alkyl or hydroxy substituted C. sub. 1 -C. sub. 8 lower alkyl, and the pharmaceutically acceptable salts thereof.

Hiv Protease Gene And Method For Its Expression

View page
US Patent:
56374887, Jun 10, 1997
Filed:
Mar 2, 1993
Appl. No.:
8/024916
Inventors:
John L. Medabalimi - Silver Spring MD
Stephen Oroszlan - Potomac MD
Peter T. Mora - Chevy Chase MD
Assignee:
The United States of America as represented by the Department of Health
and Human Services - Washington DC
International Classification:
C12N 1549
C12N 1563
C12N 1570
C12P 2102
US Classification:
4351723
Abstract:
The invention is a synthetic DNA sequence for encoding a specific enzyme or protease. The protease is essential for the completion (replication) of an infective human immunodeficiency virus (HIV). The invented gene is desirable for the expression of the protease by recombinant methodology in prokaryotic and/or eukaryotic cells and the production of a commercially desirable amount of the protease for biochemical and physical characterization, necessary to find effective inhibitor of the protease, and thereby to block the production of infectious human immunodeficiency virus (HIVs).

2,3-Epoxy Alcohols, Acids And Derivatives As Anti Retroviral Chemotherapeutic Agents

View page
US Patent:
61535893, Nov 28, 2000
Filed:
Dec 15, 1992
Appl. No.:
7/991251
Inventors:
Jeffrey J. Blumenstein - Germantown MD
Christopher J. Michejda - Potomac MD
Stephen Oroszlan - Potomac MD
Terry Copeland - Frederick MD
Assignee:
The United States of America as represented by the Department of Health
and Human Services - Washington DC
International Classification:
A61K 31336
A61K 3805
C07D30312
C07K 506
US Classification:
514 19
Abstract:
The present invention is related to compounds, compositions and methods of treating viral infections. Compounds of the present invention have the following general formula: ##STR1## wherein R is selected from --CH. sub. 2 OH, --CO. sub. 2 R. sup. 2, --CONR. sup. 3 R. sup. 4, or COR. sup. 5, wherein R. sup. 2 is hydrogen or a lower alkyl group, R. sup. 3 and R. sup. 4 are each independently hydrogen or a lower alkyl group, R. sup. 5 is an amino acid residue bound via a terminal nitrogen or peptide having at least two amino acid residues; and wherein R. sup. 1 is C. sub. 5 -C. sub. 13 alkyl, aryl, aralkyl, aralkyl(lower alkyl)ether, or C. sub. 5 -C. sub. 13 alkyl(lower alkyl)ether.

Human Immunodeficiency Virus Specific Proteolytic Enzyme And A Method For Its Synthesis And Renaturation

View page
US Patent:
53546830, Oct 11, 1994
Filed:
Jul 30, 1993
Appl. No.:
8/100703
Inventors:
Stephen Oroszlan - Potomac MD
Terry D. Copeland - Frederick MD
Assignee:
The United States of America as represented by the Department of Health
and Human Services - Washington DC
International Classification:
C12N 950
C12N 704
US Classification:
435219
Abstract:
HIV protease necessary for the natural synthesis of HIV has been identified and sequenced. This antibody cross reacts with the protease of HIV-2. In addition, a method for producing synthetic HIV-1 and HIV-2 protease having the correct stereospecific conformation and specific HIV proteolytic activity has been achieved. Assays for the synthetic proteases using synthetic peptide substrates have been developed.

Design And Construction Of Non-Infectious Human Retroviral Mutants Deficient In Genomic Rna

View page
US Patent:
56747209, Oct 7, 1997
Filed:
Jan 3, 1994
Appl. No.:
8/176682
Inventors:
Robert J. Gorelick - Braddock Heights MD
Larry O. Arthur - Walkersville MD
Alan Rein - Takoma Park MD
Louis E. Henderson - Mount Airy MD
Stephen Oroszlan - Potomac MD
Assignee:
United States of America - Washington DC
International Classification:
C12N 1300
C12P 2106
C07K 100
A61K 3921
US Classification:
4351723
Abstract:
The present invention defines a biological role for the following sequence of amino acids that is found in the nucleocapsid domain of the gag precursor polyproteins of all replication-competent retroviruses: -Cys-X-X-Cys-X-X-X-X-His-X-X-X-X-Cys- wherein X represents variable amino acids. The invariant residues constitute part of a vital protein structure, at least one of which are found in all retroviruses and which are involved in the selection and packaging of genomic viral RNA into infectious virus particles. Disruption of this structure leads to the formation of virus-like particles which appear to be structurally normal, but which do not contain the normal complement of viral RNA. Therefore, their infectivity is drastically reduced or completely eliminated. The infectivity of any retrovirus, including human retroviruses, and more particularly human immunodeficiency virus (HIV), can be drastically reduced or completely eliminated by generating mutants that lack some or all of the invariant residues required to form the structure.

Isbn (Books And Publications)

Viral Proteinases As Targets for Chemotherapy

View page
Author

Stephen Oroszlan

ISBN #

0879693355

Control profile
Stephen G Oroszlan from Potomac, MD, age ~97 Get Report